Tildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis

Tildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis

Background

Tildrakizumab, a treatment for moderate-to-severe plaque psoriasis, was evaluated for its real-world effectiveness and safety over 64 weeks.

Methods

Adults with moderate-to-severe plaque psoriasis received tildrakizumab 100 mg at specified intervals. Effectiveness was measured using body surface area affected, Physician Global Assessment, and Psoriasis Area and Severity Index. Adverse events were also monitored.

Results

Out of 55 patients, 45 completed the study and 36 received all doses of tildrakizumab. The treatment led to significant improvements in BSA, sPGA, and PASI scores. The majority of patients achieved substantial improvement in PASI scores at week 52. No adverse events were considered related to tildrakizumab treatment.

Conclusions

Tildrakizumab demonstrated effectiveness in real-world settings for adult patients with moderate-to-severe plaque psoriasis, with no new safety concerns.

Clinical Trials and Practical Solutions

Clinical trials play a crucial role in developing safe and effective treatments. It’s essential to translate their benefits into everyday medical practice. Our AI-driven platform, DocSym, consolidates ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians.

In today’s healthcare environment, streamlining operations is vital. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally.

By leveraging AI, clinics can enhance their workflows, improve patient outcomes, and reduce paper-based routines. Learn more about how we can help at aidevmd.com.